Bril Fernando, Elbert Alicia
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham (UAB), AL, USA; UAB Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Centro de Enfermedades Renales e Hipertension Arterial (CEREHA), Buenos Aires, Argentina.
Metabolism. 2025 Jan;162:156066. doi: 10.1016/j.metabol.2024.156066. Epub 2024 Nov 17.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic disease characterized by insulin resistance and lipotoxicity. Its association with type 2 diabetes, cardiovascular disease, liver cirrhosis, and hepatocellular carcinoma are well described. However, the association of MASLD and extra-hepatic cancers has received significantly less attention. This narrative review will summarize the conflicting evidence regarding the association between MASLD and cancers of the urinary system, including renal cell carcinoma, urothelial carcinoma, and prostate adenocarcinoma. It will explore potential mechanisms that could be responsible for a higher risk of urinary system cancers in patients with MASLD. We hope that our comprehensive assessment of the literature will help the readers to better interpret the available evidence.
代谢功能障碍相关脂肪性肝病（MASLD）是一种以胰岛素抵抗和脂毒性为特征的全身性疾病。其与2型糖尿病、心血管疾病、肝硬化和肝细胞癌的关联已有充分描述。然而，MASLD与肝外癌症的关联受到的关注要少得多。这篇叙述性综述将总结关于MASLD与泌尿系统癌症（包括肾细胞癌、尿路上皮癌和前列腺腺癌）之间关联的相互矛盾的证据。它将探讨可能导致MASLD患者泌尿系统癌症风险较高的潜在机制。我们希望我们对文献的全面评估将帮助读者更好地解读现有证据。
